Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
source: pixabay.com

Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars

According to a story from ankylosingspondylitisnews.com, a significant proportion of patients stopped taking a biosimilar for infliximab within six months of transitioning to the new medication. This suggests that the…

Continue Reading Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Source: Pixabay.com

New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising

According to a story from The Irish Times, a new campaign is encouraging people with the rare lung condition idiopathic pulmonary fibrosis to keep exercising. The campaign is centered around…

Continue Reading New Campaign Encourages Idiopathic Pulmonary Fibrosis Patients to Keep Exercising
Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold
source: pixabay.com

Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold

According to a story from genengnews.com, the pharmaceutical company Solid Biosciences is pledging to continue developing its investigation drug candidate SGT-001 for Duchenne muscular dystrophy. This is despite its clinical…

Continue Reading Company Continues to Back an Experimental Therapy for Duchenne Muscular Dystrophy Despite Clinical Hold